Related Experiment Video

Updated: Aug 6, 2026

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

[Bundle-branch block in the course of myocardial infarction. Recent advances]

Antonio Di Chiara, Ricarda Marinigh

    Recenti Progressi in Medicina
    |August 18, 2006
    PubMed

    Insights

    Right bundle-branch block (RBBB) in anterior ST-elevation myocardial infarction (STEMI) increases mortality risk. New left bundle-branch block (LBBB) after STEMI indicates significant damage and worse prognosis.

    Area of Science:

    • Cardiology
    • Electrocardiography
    • Clinical Trials

    Background:

    • Bundle-branch block (BBB) complicates diagnosis and prognosis in acute myocardial infarction (MI).
    • Differentiating between left BBB (LBBB) and right BBB (RBBB), and new-onset versus pre-existing BBB, is crucial.
    • BBB can mask electrocardiographic signs of ST-elevation MI (STEMI).

    Discussion:

    • Analysis of the HERO-2 trial explored prognostic differences based on BBB type during early acute MI.
    • The presence of RBBB in anterior STEMI is linked to increased mortality.
    • RBBB in inferior infarction does not independently worsen prognosis.

    Key Insights:

    • Pre-existing LBBB is associated with poorer pre-infarction characteristics and worse prognosis.
    • New-onset LBBB post-MI signifies ischemic conduction damage and carries independent negative prognostic value.
    • Understanding BBB mechanisms and prognostic implications in acute MI is essential.

    Outlook:

    • Further research into the specific mechanisms linking BBB types to MI outcomes is warranted.
    • Clinical guidelines should emphasize the prognostic significance of different BBB presentations in acute MI.
    • Integration of BBB assessment into risk stratification protocols for MI patients is recommended.

    Related Concept Videos

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Dysrhythmias VI: Management of Dysrhythmias01:25

    Dysrhythmias VI: Management of Dysrhythmias

    Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...